Insulin glargine U-300
TOUJEO
What it isConcentrated long-acting insulin-receptor agonist; basal treatment of diabetes mellitus.
Why this oneIts smaller subcutaneous depot releases more smoothly and lasts longer than standard-concentration glargine.
What limits itHypoglycemia remains dose-limiting; never withdraw it from the pen or substitute by volume, and titrate cautiously.
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Diabetes mellitus, type 1 (glycemic control) | Adults and pediatric ≥6 yr | ~1/3 to 1/2 of total daily insulin dose (total daily ~0.2-0.4 units/kg) | Individualized | Individualized |
| Diabetes mellitus, type 2 (glycemic control) | Adults and pediatric ≥6 yr | 0.2 units/kg QD | Individualized | Individualized |
Titration No more frequently than every 3 to 4 days
Renal Not formally studied; frequent glucose monitoring and dose adjustment may be needed
Hepatic Not formally studied; frequent glucose monitoring and dose adjustment may be needed
U-300 concentration; on unit-for-unit basis has lower glucose-lowering effect than Lantus (U-100)
Instructions
- Inject subcutaneously once daily at the same time each day (abdomen, thigh, or deltoid); rotate injection sites
- Do not administer intravenously or in an insulin pump
- Do not dilute or mix with any other insulin or solution
- Do not transfer from the prefilled pen into a syringe
Contraindications
- During episodes of hypoglycemia
Cautions
- Never share pen between patients
- Hyper- or hypoglycemia with changes in insulin regimen
- Hypoglycemia (may be life-threatening)
- Hypoglycemia due to medication errors
- Hypersensitivity reactions including anaphylaxis
- Hypokalemia
- Fluid retention/heart failure with concomitant thiazolidinediones
Adverse reactions
- Hypoglycemia
- Allergic reactions
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
- Edema
- Weight gain
Pregnancy Published studies have not reported a clear association with adverse developmental outcomes
Lactation Limited/no data on presence in human milk; endogenous insulin is present in human milk
NO BOXED WARNINGS
Classes and tags
Clinical profile
Mechanism of action: Insulin glargine U-300 ballicule
